Interview with Greg B. Scott, President & Founder, ChinaBio® LLC
This is our first meeting in Shanghai after being based in Beijing for two months – what if any are the differences between the two cities? At the top level,…
Address: ChinaBio® LLC Biotech VC Plaza Zhangjiang Hi-Tech Park 780 Cailun Road, Suite 822 Pudong New Area, Shanghai P.R. China 201203 ,China
Tel: -5823
Web: http://www.chinabiollc.com/
Since its founding in January, 2007, ChinaBio® LLC has rapidly launched a number of initiatives accelerating the globalization of China’s life science industry. ChinaBio has helped China companies raise nearly $500 million and global life science companies identify over 400 licensing and acquisition opportunities in China.
• Conferences: ChinaBio organizes the premier life science investment and partnering conferences in China, having attracted over 4,000 attendees. • Consulting: ChinaBio works with global life science companies and China entrepreneurs to define and execute a successful global strategy. • Transactions: ChinaBio helps companies secure partnerships and acquisitions and access private and government funding in China. • Publishing: ChinaBio® Today is the most widely read online and email newsletter on China’s life science industry.
This is our first meeting in Shanghai after being based in Beijing for two months – what if any are the differences between the two cities? At the top level,…
The only company in our Summer 2020 edition of InFocus: 5 Biotechs to Watch in China to be helmed by a non-founding CEO, I-Mab Biopharma has advanced since its establishment…
Dr Zaiqi Wang, chairman and CEO of Chinese oncology biotech InxMed, highlights the vital importance of combination therapies in cancer treatment, assesses the level of innovation in China, and outlines…
It has been just over two years since the Hong Kong Stock Exchange (HKEX) revised its listing rules to allow pre-revenue biotechs to IPO as long as they met certain…
Probably one of the most recognisable Chinese biotechs globally, Zai Lab may only be seven years old but the company has progressed rapidly in becoming a NASDAQ-listed company with not…
On 30 April 2018, Hong Kong Stock Exchange’s (HKEX’s) introduced a number of reforms to allow and support the listing of pre-profit biotech companies. Nearly 2.5 years later, 20 companies…
A roundup of latest news from Chinese pharma and biotech, including a record high share price for Hansoh, strategic healthcare partnerships, venture capital gains, and recent IPO news from Sunshine…
The completion of the Human Genome Project (HGP) in April 2003 with the publication of the first human genome sequence is probably one of the most significant landmarks in humanity’s…
With its brand new hub in Shanghai dedicated to research, business development and venture funding, German pharma giant Boehringer Ingelheim is taking a step further toward accessing innovation from the…
Dr Qing Liu, Arctic Vision’s VP for Clinical & Regulatory Affairs, shares her key priorities and the potential for top-line ophthalmological innovations in the Chinese market. Unmet medical needs…
Dr Yi (York) Chen, VP for operations and commercial planning at Arctic Vision shares his priorities, his wide experience of ophthalmology product launches in China, and how the company is…
Dr Jin Li explains Chinese firm HitGen’s unique drug discovery technology platform, how its ability to screen billions of molecules has the potential to significantly increase success rates in early…
A roundup of the latest from Chinese pharma and biotech, including Boehringer Ingelheim’s new Shanghai R&D hub, new HKEX IPO successes for Chinese firms, further progress for Clover’s COVID-19 vaccine…
See our Cookie Privacy Policy Here
